# US 2024/0197873 A1 · Modified tumor-infiltrating lymphocyte and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197873 A1
- Document ID: US20240197873A1
- Status: Published application
- Kind: A1
- Application number: 18/556,511
- Filed: 2022-04-22
- Published: 2024-06-20
- Earliest claimed: 2021-04-23
- Assignees: Suzhou Grit Biotechnology Co., Ltd.; Zhuhai Tuoyu Biotechnology Co., Ltd.; Shanghai Grit Biotechnology Co., Ltd.; Zhuhai Grit Biotechnology Co., Ltd.
- Applicants: Suzhou Grit Biotechnology Co., Ltd.; Zhuhai Tuoyu Biotechnology Co., Ltd.; Shanghai Grit Biotechnology Co., Ltd.; Zhuhai Grit Biotechnology Co., Ltd.
- Inventors: Yarong LIU; Jingwei SUN; Jiahui JIN
- Web page: https://patentgrep.com/patent/US20240197873A1

## CPC

- C07K 14/5443: {IL-15}
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/35: Cytokines
- A61K 40/42: Cancer antigens
- A61P 35/00: Antineoplastic agents
- C07K 14/7155: {for interleukins [IL]}
- C12N 5/0636: {T lymphocytes}
- C12N 15/86: Viral vectors
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/57: Skin; melanoma
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C12N 2501/2302: Interleukin-2 (IL-2)
- C12N 2501/2315: Interleukin-15 (IL-15)
- C12N 2501/51: B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
- C12N 2501/515: CD3, T-cell receptor complex
- C12N 2502/00: Coculture with; Conditioned medium produced by
- C12N 2502/11: blood or immune system cells
- C12N 2510/00: Genetically modified cells
- C12N 2740/10043: viral genome or elements thereof as genetic vector
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided are modified tumor-infiltrating lymphocyte and the use thereof, in particular provided is a method for culturing the tumor-infiltrating lymphocyte (TIL), which comprises increasing the expression and/or enhancing the activity of at least one cytokine of the TIL. Also provided is a method for preventing and/or treating tumors by using the tumor-infiltrating lymphocyte.

## Claims

### Claim 1

A method for culturing tumor-infiltrating lymphocytes (TILs), wherein the method comprising: improving the expression and/or enhancing the activity of at least one cytokine of the TILs, and co-culturing the TILs with feeder cells after contacting the TILs with T cell activators and/or T cell growth factors for a period of time.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the method comprising: improving the expression and/or enhancing the activity of at least one cytokine of the TILs after co-culturing the TILs with the feeder cells.

### Claim 3 (depends on 1, 2)

The method according to any one of claims 1-2, wherein the method comprising: improving the expression and/or enhancing the activity of at least one cytokine of the TILs before co-culturing the TILs with the feeder cells.

### Claim 4 (depends on 1, 2, 3)

The method according to any one of claims 1-3, wherein the method comprising: improving the expression and/or enhancing the activity of at least one cytokine of the TILs after contacting the TILs with the T cell activators and/or the T cell growth factors and before co-culturing the TILs with the feeder cells.

### Claim 5 (depends on 1, 2, 3, 4)

The method according to any one of claims 1-4, wherein the method comprising: improving the expression and/or enhancing the activity of at least one cytokine of the TILs substantially simultaneously with contacting the TILs with the T cell activators and/or the T cell growth factors.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method according to any one of claims 1-5, wherein the method comprising: improving the expression and/or enhancing the activity of at least one cytokine of the TILs substantially simultaneously with co-culturing the TILs with the feeder cells.

### Claim 7

A method for culturing tumor-infiltrating lymphocytes (TILs), wherein the method comprising: improving the expression and/or enhancing the activity of at least one cytokine of the TILs, wherein the TILs comprise TILs obtained by co-culturing with feeder cells after contacting the TILs with T cell activators and/or T cell growth factors for a period of time.

### Claim 8

A method for culturing tumor-infiltrating lymphocytes (TILs), wherein the method comprising: co-culturing the TILs with feeder cells after contacting the TILs with T cell activators and/or T cell growth factors for a period of time, wherein the TILs comprise TTLs obtained by improving the expression and/or enhancing the activity of at least one cytokine of the TILs.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method according to any one of claims 1-8, wherein TILs obtained by improving the expression and/or enhancing the activity of at least one cytokine of the TTLs show improved TIL properties, compared to TTLs with unchanged expression and/or activity of the cytokine.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the improved TIL properties comprise one or more properties selected from the group consisting of: increased number of TIL cells, increased proportion of viable cells, enhanced persistence, improved proportion of T cell subpopulations, enhanced cytokine secretion capacity, enhanced tumor cell killing ability, enhanced T cell receptor (TCR) clonal diversity, and increased number of TIL cells in tissues.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the improved proportion of T cell subpopulations comprises one or more subpopulations selected from the group consisting of: increased proportion of central memory T cells, decreased proportion of regulatory T cells, increased proportion of activated T cells, increased proportion of tumor-specific T cells, and increased proportion of stem cell-like T cells.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method according to any one of claims 1-11, wherein the step of improving the expression and/or enhancing the activity of at least one cytokine of the TILs comprises introducing a nucleic acid encoding the cytokine into the TILs.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the step of improving the expression and/or enhancing the activity of at least one cytokine of the TILs comprises introducing a vector comprising the nucleic acid into the TILs.

### Claim 14 (depends on 12, 13)

The method according to any one of claims 12-13, wherein the method comprises integrating the nucleic acid encoding the cytokine into a genome of the TILs.

### Claim 15 (depends on 13, 14)

The method according to any one of claims 13-14, wherein the vector comprises a viral vector.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the viral vector comprises a retroviral vector.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the retroviral vector comprises a lentiviral vector.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The method according to any one of claims 1-17, wherein the cytokine comprises interleukin (IL).

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method according to any one of claims 1-18, wherein the cytokine comprises interleukin-15 (IL-15) and/or a functionally active fragment thereof.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the IL-15 comprises membrane-anchored IL-15 and/or secreted IL-15.

### Claim 21 (depends on 19, 20)

The method according to any one of claims 19-20, wherein the IL-15 comprises an IL-15 domain.

### Claim 22 (depends on 21)

The method according to claim 21, wherein the IL-15 domain comprises an amino acid sequence as shown in SEQ ID NO: 3.

### Claim 23 (depends on 19, 20, 21, 22)

The method according to any one of claims 19-22, wherein the IL-15 comprises an IL-15Ra extracellular domain.

### Claim 24 (depends on 23)

The method according to claim 23, wherein the IL-15Ra extracellular domain comprises an amino acid sequence as shown in SEQ ID NO: 16.

### Claim 25 (depends on 23, 24)

The method according to any one of claims 23-24, wherein the IL-15 domain is directly or indirectly linked to the IL-15Ra extracellular domain.

### Claim 26 (depends on 25)

The method according to claim 25, wherein the indirect linkage comprises linking through a linker.

### Claim 27 (depends on 26)

The method according to claim 26, wherein the linker comprises an amino acid sequence selected from the group consisting of: SEQ ID NOs: 4-10, (SEQ ID NO: 11)l, (SEQ ID NO: 12)m, (SEQ ID NO: 13)n, (SEQ ID NO: 14)p, and (SEQ ID NO: 15)q, and any combination of the above, wherein l, m, n, p, and q are each independently at least 1.

### Claim 28 (depends on 19, 20, 21, 22, 23, 24, 25, 26, 27)

The method according to any one of claims 19-27, wherein the IL-15 comprises a transmembrane domain.

### Claim 29 (depends on 28)

The method according to claim 28, wherein the transmembrane domain comprises an amino acid sequence as shown in any one of SEQ ID NOs: 17-22.

### Claim 30 (depends on 28, 29)

The method according to any one of claims 28-29, wherein the transmembrane domain is directly or indirectly linked to the IL-15Ra extracellular domain.

### Claim 31 (depends on 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method according to any one of claims 19-30, wherein the IL-15 comprises an intracellular domain.

### Claim 32 (depends on 31)

The method according to claim 31, wherein the intracellular domain comprises an amino acid sequence as shown in any one of SEQ ID NOs: 23-26.

### Claim 33 (depends on 31, 32)

The method according to any one of claims 31-32, wherein the intracellular domain is directly or indirectly linked to the transmembrane domain.

### Claim 34 (depends on 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The method according to any one of claims 19-33, wherein the IL-15 comprises a signal peptide domain.

### Claim 35 (depends on 34)

The method according to claim 34, wherein the signal peptide domain comprises an amino acid sequence as shown in SEQ ID NO: 2.

### Claim 36 (depends on 34, 35)

The method according to any one of claims 34-35, wherein the signal peptide domain is directly or indirectly linked to the IL-15 domain.

### Claim 37 (depends on 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The method according to any one of claims 19-36, wherein the functionally active fragment of the IL-15 comprises an amino acid sequence as shown in SEQ ID NO: 3.

### Claim 38 (depends on 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The method according to any one of claims 19-37, wherein the IL-15 comprises an amino acid sequence as shown in SEQ ID NO: 1.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The method according to any one of claims 1-38, wherein the enhanced expression of the cytokine comprises an enhanced synthesis and/or secretion of the cytokine.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The method according to any one of claims 1-39, wherein the proportion of cells expressing the cytokine in the TILs obtained by improving the expression and/or enhancing the activity of at least one cytokine of the TTLs is increased, compared to TILs with unchanged expression and/or activity of the cytokine.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The method according to any one of claims 1-40, wherein the proportion of cells expressing the cytokine in the TILs obtained by improving the expression and/or enhancing the activity of at least one cytokine of the TILs is increased by at least about 5% or above, compared to TTLs with unchanged expression and/or activity of the cytokine.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The method according to any one of claims 1-41, wherein in the TTLs obtained by improving the expression and/or enhancing the activity of at least one cytokine of the TILs, the proportion of cells expressing the cytokine is at least about 5% or above.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method according to any one of claims 1-42, wherein the method further comprising: subjecting TILs derived from tumor tissues and not expanded in vitro to at least one stage of in vitro expansion, and co-culturing the TILs with the feeder cells during the at least one stage of in vitro expansion.

### Claim 44 (depends on 43)

The method according to claim 43, wherein the method comprises co-culturing the TILs with the feeder cells during a single stage of in vitro expansion.

### Claim 45 (depends on 43, 44)

The method according to any one of claims 43-44, wherein during the single stage of in vitro expansion, the method comprises increasing the expression of at least one cytokine of the TILs and/or enhancing the activity thereof, and co-culturing the TILs with the feeder cells.

### Claim 46 (depends on 43, 44, 45)

The method according to any one of claims 43-45, wherein the method comprises subjecting the TILs derived from tumor tissues and not expanded in vitro to a first stage of in vitro expansion and a second stage of in vitro expansion, and during the second stage of in vitro expansion, co-culturing the TILs with the feeder cells.

### Claim 47 (depends on 46)

The method according to claim 46, wherein the first stage of in vitro expansion is carried out for at least about 7 days.

### Claim 48 (depends on 46, 47)

The method according to any one of claims 46-47, wherein the first stage of in vitro expansion is carried out for about 7 days to about 14 days.

### Claim 49 (depends on 46, 47, 48)

The method according to any one of claims 46-48, wherein the second stage of in vitro expansion is carried out for at least about 7 days.

### Claim 50 (depends on 46, 47, 48, 49)

The method according to any one of claims 46-49, wherein the second stage of in vitro expansion is carried out for about 7 days to about 14 days.

### Claim 51 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)

The method according to any one of claims 1-50, comprising co-culturing the TTLs with the feeder cells after contacting the TILs with the T cell activators and/or the T cell growth factors for at least about 2 hours.

### Claim 52 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The method according to any one of claims 1-51, comprising the co-culturing TILs with the feeder cells after contacting the TILs with the T cell activators and/or the T cell growth factors for about 6 hours to about 72 hours.

### Claim 53 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The method according to any one of claims 1-52, comprising co-culturing the TTLs with the feeder cells after contacting the TILs with the T cell activators and/or the T cell growth factors for about 12 hours to about 48 hours.

### Claim 54 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The method according to any one of claims 1-52, comprising co-culturing the TTLs with the feeder cells after contacting the TILs with the T cell activators and/or the T cell growth factors for about 6 hours, about 12 hours, about 24 hours, about 48 hours, or about 72 hours.

### Claim 55 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The method according to any one of claims 1-54, wherein the feeder cells comprise antigen-presenting cells.

### Claim 56 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

The method according to any one of claims 1-55, wherein the feeder cells comprise one or more cells selected from the group consisting of: peripheral mononuclear cells, dendritic cells, and artificial antigen-presenting cells.

### Claim 57 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

The method according to any one of claims 1-56, wherein the feeder cells are peripheral mononuclear cells.

### Claim 58 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The method according to any one of claims 1-57, wherein the feeder cells are irradiated feeder cells.

### Claim 59 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

The method according to any one of claims 1-58, wherein the step of co-culturing the TILs with the feeder cells comprises contacting the surface of the feeder cells with the surface of the TILs.

### Claim 60 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method according to any one of claims 1-59, wherein the step of co-culturing the TILs with the feeder cells comprises adding the feeder cells into the cell culture medium of the TTLs.

### Claim 61 (depends on 60)

The method according to claim 60, wherein the method comprising adding the feeder cells into the cell culture medium of the TILs at a proportion of the feeder cells to the TILs from about 40:1 to about 400:1.

### Claim 62 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

The method according to any one of claims 1-61, wherein the method further comprising: subjecting TILs derived from tumor tissues and not expanded in vitro to at least one stage of in vitro expansion, wherein contacting the TILs with the T cell activators during the at least one stage of in vitro expansion.

### Claim 63 (depends on 62)

The method according to claim 62, wherein contacting the TILs with the T cell activators during the single stage of in vitro expansion.

### Claim 64 (depends on 62, 63)

The method according to any one of claims 62-63, wherein the method comprises increasing the expression of at least one cytokine of the TILs and/or enhancing the activity thereof, and contacting the TILs with the T cell activators during the single stage of in vitro expansion.

### Claim 65 (depends on 62, 63, 64)

The method according to any one of claims 62-64, wherein the method comprises subjecting the TILs derived from tumor tissues and not expanded in vitro to the first stage of in vitro expansion and the second stage of in vitro expansion, and during the second stage of in vitro expansion, contacting the TILs with the T cell activators.

### Claim 66 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The method according to any one of claims 1-65, wherein the T cell activators comprise one or more activators selected from the group consisting of: cluster of differentiation 80 (CD80), CD86, CD276, 4-1BB ligand (4-1BBL), CD27, CD30, CD134, CD275, CD40, CD258, and the functionally active fragments thereof.

### Claim 67 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

The method according to any one of claims 1-66, wherein the T cell activators comprise agonists of one or more targets selected from the group consisting of: CD3, CD28, herpes virus entry mediator (HVEM), CD40L, OX40, and 4-1BB.

### Claim 68 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

The method according to any one of claims 1-67, wherein the T cell activators comprise a CD3 agonist and/or a CD28 agonist.

### Claim 69 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68)

The method according to any one of claims 1-68, wherein the T cell activators comprise a CD3 agonist.

### Claim 70 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69)

The method according to any one of claims 1-69, wherein the T cell activators comprise an anti-CD3 antibody and/or an antigen-binding fragment thereof.

### Claim 71 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70)

The method according to any one of claims 1-70, wherein the T cell activators comprise a CD28 agonist.

### Claim 72 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71)

The method according to any one of claims 1-71, wherein the T cell activators comprise an anti-CD28 antibody and/or an antigen-binding fragment thereof, CD80 and/or a functionally active fragment thereof and/or CD86 and/or a functionally active fragment thereof.

### Claim 73 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72)

The method according to any one of claims 1-72, wherein the step of contacting the TTLs with the T cell activators comprises one or more ways selected from the group consisting of: (1) adding the T cell activators into the cell culture medium of the TILs; (2) adding engineered cells expressing the T cell activators into the cell culture medium of the TILs; and (3) adding a solid medium comprising the T cell activators into the cell culture medium of the TTLs.

### Claim 74 (depends on 73)

The method according to claim 73, wherein the initial concentration of each of the T cell activators in the cell culture medium of the TILs is each independently at least about 30 ng/mL.

### Claim 75 (depends on 73, 74)

The method according to any one of claims 73-74, wherein the initial concentration of each of the T cell activators in the cell culture medium of the TILs is each independently about 30 ng/mL to about 300 ng/mL.

### Claim 76 (depends on 73, 74, 75)

The method according to any one of claims 73-75, wherein the diameter of the solid medium is about 500 nm to about 10 μm.

### Claim 77 (depends on 73, 74, 75, 76)

The method according to any one of claims 73-76, wherein the diameter of the solid medium is about 1 nm to about 500 nm.

### Claim 78 (depends on 76, 77)

The method according to any one of claims 76-77, wherein the diameter of the solid medium is measured by transmission electron microscopy.

### Claim 79 (depends on 73, 74, 75, 76, 77, 78)

The method according to any one of claims 73-78, wherein the solid medium comprises a polymer.

### Claim 80 (depends on 73, 74, 75, 76, 77, 78, 79)

The method according to any one of claims 73-79, wherein the amount of each of the T cell activators comprised in each mg of the solid medium is each independently at least about 25 μg.

### Claim 81 (depends on 73, 74, 75, 76, 77, 78, 79, 80)

The method according to any one of claims 73-80, comprising adding the solid medium comprising the T cell activators into the cell culture medium of the TILs at a proportion of the solid medium to the TILs from about 2:1 to about 1:2.

### Claim 82 (depends on 73, 74, 75, 76, 77, 78, 79, 80, 81)

The method according to any one of claims 73-81, comprising adding the solid medium comprising the T cell activators into the cell culture medium of the TILs at a proportion of the solid medium to the TILs from about 1:100 to about 1:2000.

### Claim 83 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82)

The method according to any one of claims 1-82, wherein the method further comprising: subjecting TILs derived from tumor tissues and not expanded in vitro to at least one stage of in vitro expansion, wherein contacting the TILs with the T cell growth factors during the at least one stage of in vitro expansion.

### Claim 84 (depends on 83)

The method according to claim 83, wherein contacting the TILs with the T cell growth factors during the single stage of in vitro expansion.

### Claim 85 (depends on 83, 84)

The method according to any one of claims 83-84, wherein contacting the TILs with the T cell activators and the T cell growth factors during the single stage of in vitro expansion.

### Claim 86 (depends on 83, 84, 85)

The method according to any one of claims 83-85, wherein subjecting the TILs derived from tumor tissues and not expanded in vitro to the first stage of in vitro expansion and the second stage of in vitro expansion, and during the second stage of in vitro expansion, contacting the TILs with the T cell growth factors.

### Claim 87 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86)

The method according to any one of claims 1-86, wherein the method comprises contacting the TILs with the T cell activators and the T cell growth factors substantially simultaneously.

### Claim 88 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87)

The method according to any one of claims 1-87, wherein the T cell growth factors are one or more factors selected from the group consisting of: IL-2, IL-7, IL-12, IL-15, IL-21, interferon γ, and the functionally active fragments thereof.

### Claim 89 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88)

The method according to any one of claims 1-88, wherein the T cell growth factors comprise IL-2 and/or a functionally active fragment thereof.

### Claim 90 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89)

The method according to any one of claims 1-89, wherein the step of contacting the TILs with the T cell growth factors comprises adding the T cell growth factors into the cell culture medium of the TILs.

### Claim 91 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90)

The method according to any one of claims 1-90, wherein the initial concentration of each of the T cell growth factors in the cell culture medium of the TILs is each independently at least about 300 IU/mL.

### Claim 92 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91)

The method according to any one of claims 1-91, wherein the TILs are TILs derived from tumor tissue debris and/or TILs resuscitated after cryopreservation.

### Claim 93 (depends on 92)

The method according to claim 92, wherein the debris has a volume of about 1 mm3 to about 27 mm3.

### Claim 94

A method for culturing tumor-infiltrating lymphocytes (TILs), comprising:
(A) contacting a first TIL population derived from tumor tissues and not expanded in vitro with T cell growth factors, wherein a second TIL population is obtained via the step (A);
(B) improving the expression and/or enhancing the activity of at least one cytokine of the second TIL population, and co-culturing the second TIL population with feeder cells after contacting the second TIL population with T cell activators and/or T cell growth factors for a period of time, wherein a third TIL population is obtained via the step (B).

### Claim 95

A method for culturing tumor-infiltrating lymphocytes (TILs), comprising:
(A) resuscitating and/or continuing culturing an in vitro TIL population to obtain a second TIL population, wherein the in vitro TIL population comprises a TIL population obtained by in vitro expansion of a first TIL population derived from tumor tissues and not expanded in vitro;
(B) improving the expression and/or enhancing the activity of at least one cytokine of the second TIL population, and co-culturing the second TIL population with feeder cells after contacting the second TIL population with T cell activators and/or T cell growth factors for a period of time, wherein a third TIL population is obtained via the step (B).

### Claim 96 (depends on 95)

The method according to claim 95, wherein the in vitro TIL population comprises a TIL population obtained by contacting the first TIL population with T cell growth factors.

### Claim 97 (depends on 95, 96)

The method according to any one of claims 95-96, wherein the in vitro TIL population comprises a TIL population obtained by cryopreserving the first TIL population.

### Claim 98 (depends on 94, 95, 96, 97)

The method according to any one of claims 94-97, wherein the step (A) is carried out for about 7 days to about 14 days.

### Claim 99 (depends on 94, 95, 96, 97, 98)

The method according to any one of claims 94-98, wherein the step (B) is carried out for about 7 days to about 14 days.

### Claim 100

A method for culturing tumor-infiltrating lymphocytes (TILs), comprising:
(A) contacting a first TIL population derived from tumor tissues and not expanded in vitro with T cell growth factors, wherein a second TIL population is obtained via the step (A);
(B) improving the expression and/or enhancing the activity of at least one cytokine of the second TIL population, and contacting the second TIL population with T cell activators and/or T cell growth factors, wherein a third TIL population is obtained via the step (B);
(C) co-culturing the third TIL population with feeder cells, wherein a fourth TIL population is obtained via the step (C).

### Claim 101

A method for culturing tumor-infiltrating lymphocytes (TILs), comprising:
(A) resuscitating and/or continuing culturing an in vitro TIL population to obtain a second TIL population, wherein the in vitro TIL population comprises a TIL population obtained by in vitro expansion of a first TIL population derived from tumor tissues and not expanded in vitro;
(B) improving the expression and/or enhancing the activity of at least one cytokine of the second TIL population, and contacting the second TIL population with T cell activators and/or T cell growth factors, wherein a third TIL population is obtained via the step (B);
(C) co-culturing the third TIL population with feeder cells, wherein a fourth TIL population is obtained via the step (C).

### Claim 102 (depends on 101)

The method according to claim 101, wherein the in vitro TIL population comprises a TIL population obtained by contacting the first TIL population with T cell growth factors.

### Claim 103 (depends on 101, 102)

The method according to any one of claims 101-102, wherein the in vitro TIL population comprises a TIL population obtained by cryopreserving the first TIL population.

### Claim 104 (depends on 100, 101, 102, 103)

The method according to any one of claims 100-103, wherein the step (A) is carried out for about 7 days to about 14 days.

### Claim 105 (depends on 100, 101, 102, 103, 104)

The method according to any one of claims 100-104, wherein the step (B) is carried out for about 0 days to about 8 days.

### Claim 106 (depends on 100, 101, 102, 103, 104, 105)

The method according to any one of claims 100-105, wherein the step (C) is carried out for about 5 days to about 14 days.

### Claim 107

A method for culturing tumor-infiltrating lymphocytes (TILs), comprising:
(A) contacting a first TIL population derived from tumor tissues and not expanded in vitro with T cell growth factors, wherein a second TIL population is obtained via the step (A);
(B) contacting the second TIL population with T cell activators and/or T cell growth factors, wherein a third TIL population is obtained via the step (B);
(C) improving the expression and/or enhancing the activity of at least one cytokine of the third TIL population, wherein a fourth TIL population is obtained via the step (C);
(D) co-culturing the fourth TIL population with feeder cells, wherein a fifth TIL population is obtained via the step (D).

### Claim 108

A method for culturing tumor-infiltrating lymphocytes (TILs), comprising:
(A) resuscitating and/or continuing culturing an in vitro TIL population to obtain a second TIL population, wherein the in vitro TIL population comprises a TIL population obtained by in vitro expansion of a first TIL population derived from tumor tissues and not expanded in vitro;
(B) contacting the second TIL population with T cell activators and/or T cell growth factors, wherein a third TIL population is obtained via the step (B);
(C) improving the expression and/or enhancing the activity of at least one cytokine of the third TIL population, wherein a fourth TIL population is obtained via the step (C);
(D) co-culturing the fourth TIL population with feeder cells, wherein a fifth TIL population is obtained via the step (D).

### Claim 109 (depends on 108)

The method according to claim 108, wherein the in vitro TIL population comprises a TIL population obtained by contacting the first TIL population with T cell growth factors.

### Claim 110 (depends on 108, 109)

The method according to any one of claims 108-109, wherein the in vitro TIL population comprises a TIL population obtained by cryopreserving the first TIL population.

### Claim 111 (depends on 107, 108, 109, 110)

The method according to any one of claims 107-110, wherein the step (A) is carried out for about 7 days to about 14 days.

### Claim 112 (depends on 107, 108, 109, 110, 111)

The method according to any one of claims 107-111, wherein the step (B) is carried out for about 0 days to about 4 days.

### Claim 113 (depends on 107, 108, 109, 110, 111, 112)

The method according to any one of claims 107-112, wherein the step (C) is carried out for about 0 days to about 4 days.

### Claim 114 (depends on 107, 108, 109, 110, 111, 112, 113)

The method according to any one of claims 107-113, wherein the step (D) is carried out for about 5 days to about 14 days.

### Claim 115 (depends on 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114)

The method according to any one of claims 94-114, wherein TTLs obtained by improving the expression and/or enhancing the activity of at least one cytokine of the TILs show improved TIL properties, compared to TILs with unchanged expression and/or activity of the cytokine.

### Claim 116 (depends on 115)

The method according to claim 115, wherein the improved TIL properties comprise one or more properties selected from the group consisting of: increased number of TIL cells, increased proportion of viable cells, enhanced persistence, improved proportion of T cell subpopulations, enhanced cytokine secretion capacity, enhanced tumor cell killing ability, enhanced T cell receptor (TCR) clonal diversity, and increased number of TIL cells in tissues.

### Claim 117 (depends on 116)

The method according to claim 116, wherein the improved proportion of T cell subpopulations comprises one or more subpopulations selected from the group consisting of: increased proportion of central memory T cells, decreased proportion of regulatory T cells, increased proportion of activated T cells, increased proportion of tumor-specific T cells, and increased proportion of stem cell-like T cells.

### Claim 118 (depends on 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117)

The method according to any one of claims 94-117, wherein the step of improving the expression and/or enhancing the activity of at least one cytokine of the TILs comprises introducing a nucleic acid encoding the cytokine into the TILs.

### Claim 119 (depends on 118)

The method according to claim 118, wherein the step of improving the expression and/or enhancing the activity of at least one cytokine of the TILs comprises introducing a vector comprising the nucleic acid into the TILs.

### Claim 120 (depends on 118, 119)

The method according to any one of claims 118-119, wherein integrating a nucleic acid encoding the cytokine into the genome of the TILs.

### Claim 121 (depends on 118, 119, 120)

The method according to any one of claims 118-120, wherein the vector comprises a viral vector.

### Claim 122 (depends on 121)

The method according to claim 121, wherein the viral vector comprises a retroviral vector.

### Claim 123 (depends on 122)

The method according to claim 122, wherein the retroviral vector comprises a lentiviral vector.

### Claim 124 (depends on 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123)

The method according to any one of claims 94-123, wherein the cytokine comprises interleukin (IL).

### Claim 125 (depends on 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124)

The method according to any one of claims 94-124, wherein the cytokine comprises interleukin-15 (IL-15) and/or a functionally active fragment thereof.

### Claim 126 (depends on 125)

The method according to claim 125, wherein the IL-15 comprises membrane-anchored IL-15 and/or secreted IL-15.

### Claim 127 (depends on 125, 126)

The method according to any one of claims 125-126, wherein the IL-15 comprises an IL-15 domain.

### Claim 128 (depends on 127)

The method according to claim 127, wherein the IL-15 domain comprises an amino acid sequence as shown in SEQ ID NO: 3.

### Claim 129 (depends on 125, 126, 127, 128)

The method according to any one of claims 125-128, wherein the IL-15 comprises an IL-15Ra extracellular domain.

### Claim 130 (depends on 129)

The method according to claim 129, wherein the IL-15Ra extracellular domain comprises an amino acid sequence as shown in SEQ ID NO: 16.

### Claim 131 (depends on 129, 130)

The method according to any one of claims 129-130, wherein the IL-15 domain is directly or indirectly linked to the IL-15Ra extracellular domain.

### Claim 132 (depends on 131)

The method according to claim 131, wherein the indirect linkage comprises linking through a linker.

### Claim 133 (depends on 132)

The method according to claim 132, wherein the linker comprises an amino acid sequence selected from the group consisting of: SEQ ID NOs: 4-10, (SEQ ID NO: 11)l, (SEQ ID NO: 12)m, (SEQ ID NO: 13)n, (SEQ ID NO: 14)p, and (SEQ ID NO: 15)q, and any combination of the above, wherein 1, m, n, p, and q are each independently at least 1.

### Claim 134 (depends on 125, 126, 127, 128, 129, 130, 131, 132, 133)

The method according to any one of claims 125-133, wherein the IL-15 comprises a transmembrane domain.

### Claim 135 (depends on 134)

The method according to claim 134, wherein the transmembrane domain comprises an amino acid sequence as shown in any one of SEQ ID NOs: 17-22.

### Claim 136 (depends on 134, 135)

The method according to any one of claims 134-135, wherein the transmembrane domain is directly or indirectly linked to the IL-15Ra extracellular domain.

### Claim 137 (depends on 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136)

The method according to any one of claims 125-136, wherein the IL-15 comprises an intracellular domain.

### Claim 138 (depends on 137)

The method according to claim 137, wherein the intracellular domain comprises an amino acid sequence as shown in any one of SEQ ID NOs: 23-26.

### Claim 139 (depends on 137, 138)

The method according to any one of claims 137-138, wherein the intracellular domain is directly or indirectly linked to the transmembrane domain.

### Claim 140 (depends on 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139)

The method according to any one of claims 125-139, wherein the IL-15 comprises a signal peptide domain.

### Claim 141 (depends on 140)

The method according to claim 140, wherein the signal peptide domain comprises an amino acid sequence as shown in SEQ ID NO: 2.

### Claim 142 (depends on 140, 141)

The method according to any one of claims 140-141, wherein the signal peptide domain is directly or indirectly linked to the IL-15 domain.

### Claim 143 (depends on 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142)

The method according to any one of claims 125-142, wherein the functionally active fragment of the IL-15 comprises an amino acid sequence as shown in SEQ ID NO: 3.

### Claim 144 (depends on 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143)

The method according to any one of claims 125-143, wherein the IL-15 comprises an amino acid sequence as shown in SEQ ID NO: 1.

### Claim 145 (depends on 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144)

The method according to any one of claims 94-144, wherein the enhanced expression of the cytokine comprises enhanced synthesis and/or secretion of the cytokine.

### Claim 146 (depends on 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145)

The method according to any one of claims 94-145, wherein the proportion of cells expressing the cytokine in the TILs obtained by improving the expression and/or enhancing the activity of at least one cytokine of the TILs is increased, compared to TILs with unchanged expression and/or activity of the cytokine.

### Claim 147 (depends on 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146)

The method according to any one of claims 94-146, wherein the proportion of cells expressing the cytokine in the TILs obtained by improving the expression and/or enhancing the activity of at least one cytokine of the TILs is increased by at least about 5% or above, compared to TILs with unchanged expression and/or activity of the cytokine.

### Claim 148 (depends on 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147)

The method according to any one of claims 94-147, wherein in the TILs obtained by improving the expression and/or enhancing the activity of at least one cytokine of the TILs, the proportion of cells expressing the cytokine is at least about 5% or above.

### Claim 149 (depends on 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148)

The method according to any one of claims 94-148, comprising co-culturing the TILs with the feeder cells after contacting the TTLs with the T cell activators and/or the T cell growth factors for at least about 2 hours.

### Claim 150 (depends on 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149)

The method according to any one of claims 94-149, comprising co-culturing the TILs with the feeder cells after contacting the TTLs with the T cell activators and/or the T cell growth factors for about 6 hours to about 72 hours.

### Claim 151 (depends on 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150)

The method according to any one of claims 94-150, comprising co-culturing the TILs with the feeder cells after contacting the TTLs with the T cell activators and/or the T cell growth factors for about 12 hours to about 48 hours.

### Claim 152 (depends on 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150)

The method according to any one of claims 94-150, comprising co-culturing the TILs with the feeder cells after contacting the TTLs with the T cell activators and/or the T cell growth factors for about 6 hours, about 12 hours, about 24 hours, about 48 hours, or about 72 hours.

### Claim 153 (depends on 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152)

The method according to any one of claims 94-152, wherein the feeder cells comprise antigen-presenting cells.

### Claim 154 (depends on 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153)

The method according to claims 94-153, wherein the feeder cells comprise one or more cells selected from the group consisting of: peripheral mononuclear cells, dendritic cells, and artificial antigen-presenting cells.

### Claim 155 (depends on 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154)

The method according to claims 94-154, wherein the feeder cells are peripheral mononuclear cells.

### Claim 156 (depends on 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155)

The method according to claims 94-155, wherein the feeder cells are irradiated feeder cells.

### Claim 157 (depends on 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156)

The method according to any one of claims 94-156, wherein the step of co-culturing the TILs with the feeder cells comprises contacting the surface of the feeder cells with the surface of the TILs.

### Claim 158 (depends on 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157)

The method according to any one of claims 94-157, wherein the step of co-culturing the TILs with the feeder cells comprises adding the feeder cells into the cell culture medium of the TTLs.

### Claim 159 (depends on 158)

The method according to claim 158, wherein the method comprises adding the feeder cells into the cell culture medium of the TILs at a proportion of the feeder cells to the TTLs from about 40:1 to about 400:1.

### Claim 160 (depends on 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159)

The method according to any one of claims 94-159, wherein the T cell activators comprise one or more activators selected from the group consisting of: cluster of differentiation 80 (CD80), CD86, CD276, 4-1BB ligand (4-1BBL), CD27, CD30, CD134, CD275, CD40, CD258, and functionally active fragments thereof.

### Claim 161 (depends on 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160)

The method according to any one of claims 94-160, wherein the T cell activators comprise agonists of one or more targets selected from the group consisting of: CD3, CD28, herpes virus entry mediator (HVEM), CD40L, OX40, and 4-1BB.

### Claim 162 (depends on 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161)

The method according to any one of claims 94-161, wherein the T cell activators comprise a CD3 agonist and/or a CD28 agonist.

### Claim 163 (depends on 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162)

The method according to any one of claims 94-162, wherein the T cell activators comprise a CD3 agonist.

### Claim 164 (depends on 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163)

The method according to any one of claims 94-163, wherein the T cell activators comprise an anti-CD3 antibody and/or an antigen-binding fragment thereof.

### Claim 165 (depends on 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164)

The method according to any one of claims 94-164, wherein the T cell activators comprise a CD28 agonist.

### Claim 166 (depends on 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165)

The method according to any one of claims 94-165, wherein the T cell activators comprise an anti-CD28 antibody and/or an antigen-binding fragment thereof, CD80 and/or a functionally active fragment thereof and/or CD86 and/or a functionally active fragment thereof.

### Claim 167 (depends on 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166)

The method according to any one of claims 94-166, wherein the step of contacting the TILs with the T cell activators comprises one or more ways selected from the group consisting of: (1) adding the T cell activators into the cell culture medium of the TILs; (2) adding engineered cells expressing the T cell activators into the cell culture medium of the TILs; and (3) adding a solid medium comprising the T cell activators into the cell culture medium of the TTLs.

### Claim 168 (depends on 167)

The method according to claim 167, wherein the initial concentration of each of the T cell activators in the cell culture medium of the TILs is each independently at least about 30 ng/mL.

### Claim 169 (depends on 167, 168)

The method according to any one of claims 167-168, wherein the initial concentration of each of the T cell activators in the cell culture medium of the TILs is each independently about 30 ng/mL to about 300 ng/mL.

### Claim 170 (depends on 167, 168, 169)

The method according to any one of claims 167-169, wherein the diameter of the solid medium is about 500 nm to about 10 m.

### Claim 171 (depends on 167, 168, 169, 170)

The method according to any one of claims 167-170, wherein the diameter of the solid medium is about 1 nm to about 500 nm.

### Claim 172 (depends on 170, 171)

The method according to any one of claims 170-171, wherein the diameter of the solid medium is measured by transmission electron microscopy.

### Claim 173 (depends on 167, 168, 169, 170, 171, 172)

The method according to any one of claims 167-172, wherein the solid medium comprises a polymer.

### Claim 174 (depends on 167, 168, 169, 170, 171, 172, 173)

The method according to any one of claims 167-173, wherein the amount of each of the T cell activators comprised in each mg of the solid medium is each independently at least about 25 μg.

### Claim 175 (depends on 167, 168, 169, 170, 171, 172, 173, 174)

The method according to any one of claims 167-174, comprising adding the solid medium comprising the T cell activators into the cell culture medium of the TILs at a proportion of the solid medium to the TILs from about 2:1 to about 1:2.

### Claim 176 (depends on 167, 168, 169, 170, 171, 172, 173, 174, 175)

The method according to any one of claims 167-175, comprising adding the solid medium comprising the T cell activators into the cell culture medium of the TILs at a proportion of the solid medium to the TILs from about 1:100 to about 1:2000.

### Claim 177 (depends on 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176)

The method according to any one of claims 94-176, wherein the method comprises contacting the TILs with the T cell activators and the T cell growth factors substantially simultaneously.

### Claim 178 (depends on 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177)

The method according to any one of claims 94-177, wherein the T cell growth factors are one or more factors selected from the group consisting of: IL-2, IL-7, IL-12, IL-15, IL-21, interferon γ, and the functionally active fragments thereof.

### Claim 179 (depends on 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178)

The method according to any one of claims 94-178, wherein the T cell growth factors comprise IL-2 and/or a functionally active fragment thereof.

### Claim 180 (depends on 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179)

The method according to any one of claims 94-179, wherein the step of contacting the TILs with the T cell growth factors comprises adding the T cell growth factors into the cell culture medium of the TILs.

### Claim 181 (depends on 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180)

The method according to any one of claims 94-180, wherein the initial concentration of each of the T cell growth factors in the cell culture medium of the TILs is each independently at least about 300 IU/mL.

### Claim 182 (depends on 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181)

The method according to any one of claims 94-181, wherein the TILs are TILs derived from tumor tissue debris and/or TILs resuscitated after cryopreservation.

### Claim 183 (depends on 182)

The method according to claim 182, wherein the debris has a volume of about 1 mm3 to about 27 mm3.

### Claim 184

A method for culturing tumor-infiltrating lymphocytes (TILs), wherein the method comprising: improving the expression and/or enhancing the activity of at least one cytokine of the TILs, and contacting the TILs with a CD28 agonist.

### Claim 185 (depends on 184)

The method according to claim 184, wherein the method comprising: improving the expression and/or enhancing the activity of at least one cytokine of the TILs after contacting the TILs with the CD28 agonist.

### Claim 186 (depends on 184, 185)

The method according to any one of claims 184-185, wherein the method comprising: improving the expression and/or enhancing the activity of at least one cytokine of the TILs before contacting the TILs with the CD28 agonist.

### Claim 187

A method for culturing tumor-infiltrating lymphocytes (TILs), wherein the method comprising: improving the expression and/or enhancing the activity of at least one cytokine of the TILs, wherein the TILs comprise TILs obtained by contacting the TTLs with a CD28 agonist.

### Claim 188

A method for culturing tumor-infiltrating lymphocytes (TILs), wherein the method comprising: contacting the TTLs with a CD28 agonist, wherein the TILs comprise TILs obtained by improving the expression and/or enhancing the activity of at least one cytokine of the TILs.

### Claim 189 (depends on 184, 185, 186, 187, 188)

The method according to any one of claims 184-188, wherein TILs obtained by improving the expression and/or enhancing the activity of at least one cytokine of the TILs show improved TIL properties, compared to TILs with unchanged expression and/or activity of the cytokine.

### Claim 190 (depends on 189)

The method according to claim 189, wherein the improved TIL properties comprise one or more properties selected from the group consisting of: increased number of TIL cells, increased proportion of viable cells, enhanced persistence, improved proportion of T cell subpopulations, enhanced cytokine secretion capacity, enhanced tumor cell killing ability, enhanced T cell receptor (TCR) clonal diversity, and increased number of TIL cells in tissues.

### Claim 191 (depends on 190)

The method according to claim 190, wherein the improved proportion of T cell subpopulations comprises one or more subpopulations selected from the group consisting of: increased proportion of central memory T cells, decreased proportion of regulatory T cells, increased proportion of activated T cells, increased proportion of tumor-specific T cells, and increased proportion of stem cell-like T cells.

### Claim 192 (depends on 184, 185, 186, 187, 188, 189, 190, 191)

The method according to any one of claims 184-191, wherein the TILs that have been contacted with the CD28 agonist during at least one stage of in vitro expansion show an improved gene editing effect, compared to corresponding TILs that have not been contacted with the CD28 agonist during the stage of in vitro expansion.

### Claim 193 (depends on 192)

The method according to claim 192, wherein the improved gene editing effect comprises enhanced gene knockout efficiency.

### Claim 194 (depends on 184, 185, 186, 187, 188, 189, 190, 191, 192, 193)

The method according to any one of claims 184-193, wherein the step of improving the expression and/or enhancing the activity of at least one cytokine of the TILs comprises introducing a nucleic acid encoding the cytokine into the TILs.

### Claim 195 (depends on 194)

The method according to claim 194, wherein the step of improving the expression and/or enhancing the activity of at least one cytokine of the TILs comprises introducing a vector comprising the nucleic acid into the TILs.

### Claim 196 (depends on 194, 195)

The method according to any one of claims 194-195, wherein integrating a nucleic acid encoding the cytokine into the genome of the TILs.

### Claim 197 (depends on 195, 196)

The method according to any one of claims 195-196, wherein the vector comprises a viral vector.

### Claim 198 (depends on 197)

The method according to claim 197, wherein the viral vector comprises a retroviral vector.

### Claim 199 (depends on 198)

The method according to claim 198, wherein the retroviral vector comprises a lentiviral vector.

### Claim 200 (depends on 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199)

The method according to any one of claims 184-199, wherein the cytokine comprises interleukin (IL).

### Claim 201 (depends on 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200)

The method according to any one of claims 184-200, wherein the cytokine comprises interleukin-15 (IL-15) and/or a functionally active fragment thereof.

### Claim 202 (depends on 201)

The method according to claim 201, wherein the IL-15 comprises membrane-anchored IL-15 and/or secreted IL-15.

### Claim 203 (depends on 201, 202)

The method according to any one of claims 201-202, wherein the IL-15 comprises an IL-15 domain.

### Claim 204 (depends on 203)

The method according to claim 203, wherein the IL-15 domain comprises an amino acid sequence as shown in SEQ ID NO: 3.

### Claim 205 (depends on 201, 202, 203, 204)

The method according to any one of claims 201-204, wherein the IL-15 comprises an IL-15Ra extracellular domain.

### Claim 206 (depends on 205)

The method according to claim 205, wherein the IL-15Ra extracellular domain comprises an amino acid sequence as shown in SEQ ID NO: 16.

### Claim 207 (depends on 205, 206)

The method according to any one of claims 205-206, wherein the IL-15 domain is directly or indirectly linked to the IL-15Ra extracellular domain.

### Claim 208 (depends on 207)

The method according to claim 207, wherein the indirect linkage comprises linking through a linker.

### Claim 209 (depends on 208)

The method according to claim 208, wherein the linker comprises an amino acid sequence selected from the group consisting of: SEQ ID NOs: 4-10, (SEQ ID NO: 11)l, (SEQ ID NO: 12)m, (SEQ ID NO: 13)n, (SEQ ID NO: 14)p, and (SEQ ID NO: 15)q, and any combination of the above, wherein 1, m, n, p, and q are each independently at least 1.

### Claim 210 (depends on 201, 202, 203, 204, 205, 206, 207, 208, 209)

The method according to any one of claims 201-209, wherein the IL-15 comprises a transmembrane domain.

### Claim 211 (depends on 210)

The method according to claim 210, wherein the transmembrane domain comprises an amino acid sequence as shown in any one of SEQ ID NOs: 17-22.

### Claim 212 (depends on 210, 211)

The method according to any one of claims 210-211, wherein the transmembrane domain is directly or indirectly linked to the IL-15Ra extracellular domain.

### Claim 213 (depends on 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212)

The method according to any one of claims 201-212, wherein the IL-15 comprises an intracellular domain.

### Claim 214 (depends on 213)

The method according to claim 213, wherein the intracellular domain comprises an amino acid sequence as shown in any one of SEQ ID NOs: 23-26.

### Claim 215 (depends on 213, 214)

The method according to any one of claims 213-214, wherein the intracellular domain is directly or indirectly linked to the transmembrane domain.

### Claim 216 (depends on 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215)

The method according to any one of claims 201-215, wherein the IL-15 comprises a signal peptide domain.

### Claim 217 (depends on 216)

The method according to claim 216, wherein the signal peptide domain comprises an amino acid sequence as shown in SEQ ID NO: 2.

### Claim 218 (depends on 216, 217)

The method according to any one of claims 216-217, wherein the signal peptide domain is directly or indirectly linked to the IL-15 domain.

### Claim 219 (depends on 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218)

The method according to any one of claims 201-218, wherein the functionally active fragment of the IL-15 comprises an amino acid sequence as shown in SEQ ID NO: 3.

### Claim 220 (depends on 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219)

The method according to any one of claims 201-219, wherein the IL-15 comprises an amino acid sequence as shown in SEQ ID NO: 1.

### Claim 221 (depends on 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220)

The method according to any one of claims 184-220, wherein the enhanced expression of the cytokine comprises an enhanced synthesis and/or secretion of the cytokine.

### Claim 222 (depends on 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221)

The method according to any one of claims 184-221, wherein the proportion of cells expressing the cytokine in the TILs obtained by improving the expression and/or enhancing the activity of at least one cytokine of the TILs is increased, compared to TTLs with unchanged expression and/or activity of the cytokine.

### Claim 223 (depends on 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222)

The method according to any one of claims 184-222, wherein the proportion of cells expressing the cytokine in the TILs obtained by improving the expression and/or enhancing the activity of at least one cytokine of the TILs is increased by at least about 5% or above, compared to TILs with unchanged expression and/or activity of the cytokine.

### Claim 224 (depends on 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223)

The method according to any one of claims 184-223, wherein in the TLs obtained by improving the expression and/or enhancing the activity of at least one cytokine of the TILs, the proportion of cells expressing the cytokine is at least about 5% or above.

### Claim 225 (depends on 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224)

The method according to any one of claims 184-224, wherein subjecting the TTLs derived from tumor tissues and not expanded in vitro to at least one stage of in vitro expansion, and wherein contacting the TILs with the CD28 agonist during the at least one stage of in vitro expansion.

### Claim 226 (depends on 225)

The method according to claim 225, wherein subjecting the TILs derived from tumor tissues and not expanded in vitro to a first stage of in vitro expansion and a second stage of in vitro expansion, and during the second stage of in vitro expansion, contacting the TILs from the first stage of in vitro expansion with the CD28 agonist.

### Claim 227 (depends on 226)

The method according to claim 226, wherein the first stage of in vitro expansion is carried out for at least about 7 days.

### Claim 228 (depends on 226, 227)

The method according to any one of claims 226-227, wherein the first stage of in vitro expansion is carried out for about 7 days to about 14 days.

### Claim 229 (depends on 226, 227, 228)

The method according to any one of claims 226-228, wherein the second stage of in vitro expansion is carried out for at least about 7 days.

### Claim 230 (depends on 226, 227, 228, 229)

The method according to any one of claims 226-229, wherein the second stage of in vitro expansion is carried out for about 7 days to about 14 days.

### Claim 231 (depends on 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230)

The method according to any one of claims 184-230, wherein the CD28 agonist comprises an anti-CD28 antibody and/or an antigen-binding fragment thereof, CD80 and/or a functionally active fragment thereof, and/or CD86 and/or a functionally active fragment thereof.

### Claim 232 (depends on 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231)

The method according to any one of claims 184-231, wherein the method further comprising: subjecting TILs derived from tumor tissues and not expanded in vitro to at least one stage of in vitro expansion, wherein contacting the TILs with other T cell activators other than the CD28 agonist during the at least one stage of in vitro expansion.

### Claim 233 (depends on 232)

The method according to claim 232, wherein during a single stage of in vitro expansion, contacting the TILs with the other T cell activators.

### Claim 234 (depends on 232, 233)

The method according to any one of claims 232-233, wherein the method comprises increasing the expression of at least one cytokine of the TILs and/or enhancing the activity thereof, and contacting the TILs with the other T cell activators during the single stage of in vitro expansion.

### Claim 235 (depends on 232, 233, 234)

The method according to any one of claims 232-234, wherein the method comprises subjecting the TILs derived from tumor tissues and not expanded in vitro to the first stage of in vitro expansion and the second stage of in vitro expansion, and during the second stage of in vitro expansion, contacting the TILs with the other T cell activators.

### Claim 236 (depends on 232, 233, 234, 235)

The method according to any one of claims 232-235, wherein the method comprises contacting the TILs with the CD28 agonist and the other T cell activators substantially simultaneously.

### Claim 237 (depends on 232, 233, 234, 235, 236)

The method according to any one of claims 232-236, wherein the other T cell activators comprise agonists of one or more targets selected from the group consisting of: CD3, HVEM, CD40L, OX40, and 4-1BB.

### Claim 238 (depends on 232, 233, 234, 235, 236, 237)

The method according to any one of claims 232-237, wherein the other T cell activators comprise a CD3 agonist.

### Claim 239 (depends on 232, 233, 234, 235, 236, 237, 238)

The method according to any one of claims 232-238, wherein the other T cell activators comprise an anti-CD3 antibody and/or an antigen-binding fragment thereof.

### Claim 240 (depends on 232, 233, 234, 235, 236, 237, 238, 239)

The method according to any one of claims 232-239, wherein the step of contacting the TILs with the CD28 agonist and the other T cell activators comprises one or more ways selected from the group consisting of: (1) adding the CD28 agonist and the other T cell activators into the cell culture medium of the TILs; (2) adding engineered cells expressing the CD28 agonist and the other T cell activators into the cell culture medium of the TILs; (3) adding a solid medium comprising the CD28 agonist and the other T cell activators into the cell culture medium of the TTLs.

### Claim 241 (depends on 240)

The method according to claim 240, wherein the initial concentration of the other T cell activators in the cell culture medium of the TILs is at least about 30 ng/mL.

### Claim 242 (depends on 240, 241)

The method according to any one of claims 240-241, wherein the initial concentration of the other T cell activators in the cell culture medium of the TILs is about 30 ng/mL to about 300 ng/mL.

### Claim 243 (depends on 240, 241, 242)

The method according to any one of claims 240-242, wherein the diameter of the solid medium is about 500 nm to about 10 m.

### Claim 244 (depends on 240, 241, 242, 243)

The method according to any one of claims 240-243, wherein the diameter of the solid medium is about 1 nm to about 500 nm.

### Claim 245 (depends on 243, 244)

The method according to any one of claims 243-244, wherein the diameter of the solid medium is measured by transmission electron microscopy.

### Claim 246 (depends on 240, 241, 242, 243, 244, 245)

The method according to any one of claims 240-245, wherein the solid medium comprises a polymer.

### Claim 247 (depends on 240, 241, 242, 243, 244, 245, 246)

The method according to any one of claims 240-246, wherein each mg of the solid medium comprises at least about 25 μg of the CD28 agonist and the other T cell activators.

### Claim 248 (depends on 240, 241, 242, 243, 244, 245, 246, 247)

The method according to any one of claims 240-247, comprising adding the solid medium comprising the CD28 agonist and the other T cell activators into the cell culture medium of the TILs at a proportion of the solid medium to the TTLs from about 2:1 to about 1:2.

### Claim 249 (depends on 240, 241, 242, 243, 244, 245, 246, 247, 248)

The method according to any one of claims 240-248, comprising adding the solid medium comprising the CD28 agonist and the other T cell activators into the cell culture medium of the TILs at a proportion of the solid medium to the TILs from about 1:100 to about 1:2000.

### Claim 250 (depends on 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249)

The method according to any one of claims 184-249, wherein the method further comprising: subjecting TILs derived from tumor tissues and not expanded in vitro to at least one stage of in vitro expansion, wherein co-culturing the TILs with feeder cells after contacting the TILs with the CD28 agonist for a period of time during the at least one stage of in vitro expansion.

### Claim 251 (depends on 250)

The method according to claim 250, wherein co-culturing the TILs with the feeder cells during the single stage of in vitro expansion.

### Claim 252 (depends on 250, 251)

The method according to any one of claims 250-251, wherein the method comprises contacting the TILs with the CD28 agonist and co-culturing with the feeder cells during the single stage of in vitro expansion.

### Claim 253 (depends on 250, 251, 252)

The method according to any one of claims 250-252, wherein the method comprises subjecting the TILs derived from tumor tissues and not expanded in vitro to the first stage of in vitro expansion and the second stage of in vitro expansion, and during the second stage of in vitro expansion, co-culturing the TILs with the feeder cells.

### Claim 254 (depends on 250, 251, 252, 253)

The method according to any one of claims 250-253, comprising co-culturing the TILs with the feeder cells after contacting the TILs with the CD28 agonist for at least about 2 hours.

### Claim 255 (depends on 250, 251, 252, 253, 254)

The method according to any one of claims 250-254, comprising co-culturing the TILs with the feeder cells after contacting the TTLs with the CD28 agonist for about 6 hours to about 72 hours.

### Claim 256 (depends on 250, 251, 252, 253, 254, 255)

The method according to any one of claims 250-255, comprising co-culturing the TILs with the feeder cells after contacting the TILs with the CD28 agonist for about 12 hours to about 48 hours.

### Claim 257 (depends on 250, 251, 252, 253, 254, 255)

The method according to any one of claims 250-255, comprising co-culturing the TILs with the feeder cells after contacting the TILs with the CD28 agonist for about 6 hours, about 12 hours, about 24 hours, about 48 hours, or about 72 hours.

### Claim 258 (depends on 250, 251, 252, 253, 254, 255, 256, 257)

The method according to any one of claims 250-257, wherein the feeder cells comprise antigen-presenting cells.

### Claim 259 (depends on 250, 251, 252, 253, 254, 255, 256, 257, 258)

The method according to any one of claims 250-258, wherein the feeder cells comprise one or more cells selected from the group consisting of: peripheral mononuclear cells, dendritic cells, and artificial antigen-presenting cells.

### Claim 260 (depends on 250, 251, 252, 253, 254, 255, 256, 257, 258, 259)

The method according to any one of claims 250-259, wherein the feeder cells are peripheral mononuclear cells.

### Claim 261 (depends on 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260)

The method according to any one of claims 250-260, wherein the feeder cells are irradiated feeder cells.

### Claim 262 (depends on 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261)

The method according to any one of claims 250-261, wherein the step of co-culturing the TILs with the feeder cells comprises contacting the surface of the feeder cells with the surface of the TILs.

### Claim 263 (depends on 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262)

The method according to any one of claims 250-262, wherein the step of co-culturing the TILs with the feeder cells comprises adding the feeder cells into the cell culture medium of the TILs.

### Claim 264 (depends on 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263)

The method according to any one of claims 250-263, comprising adding the feeder cells into the cell culture medium of the TILs at a proportion of the feeder cells to the TILs from about 40:1 to about 400:1.

### Claim 265 (depends on 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264)

The method according to any one of claims 184-264, wherein the method further comprising: subjecting TILs derived from tumor tissues and not expanded in vitro to at least one stage of in vitro expansion, wherein contacting the TILs with T cell growth factors during the at least one stage of in vitro expansion.

### Claim 266 (depends on 265)

The method according to claim 265, comprising contacting the TILs with the T cell growth factors during the single stage of in vitro expansion.

### Claim 267 (depends on 265, 266)

The method according to any one of claims 265-266, comprising contacting the TILs with the CD28 agonist and the T cell growth factors during the single stage of in vitro expansion.

### Claim 268 (depends on 265, 266, 267)

The method according to any one of claims 265-267, wherein the method comprises subjecting the TILs derived from tumor tissues and not expanded in vitro to the first stage of in vitro expansion and the second stage of in vitro expansion, and during the second stage of in vitro expansion, contacting the TILs with the T cell growth factors.

### Claim 269 (depends on 265, 266, 267, 268)

The method according to any one of claims 265-268, comprising contacting the TILs with the CD28 agonist and the T cell growth factors substantially simultaneously.

### Claim 270 (depends on 265, 266, 267, 268, 269)

The method according to any one of claims 265-269, wherein the T cell growth factors are one or more factors selected from the group consisting of: IL-2, IL-7, IL-12, IL-15, IL-21, interferon γ, and functionally active fragments thereof.

### Claim 271 (depends on 265, 266, 267, 268, 269, 270)

The method according to any one of claims 265-270, wherein the T cell growth factors comprise IL-2 and/or a functionally active fragment thereof.

### Claim 272 (depends on 265, 266, 267, 268, 269, 270, 271)

The method according to any one of claims 265-271, wherein the step of contacting the TILs with the T cell growth factors comprises adding the T cell growth factors into the cell culture medium of the TILs.

### Claim 273 (depends on 265, 266, 267, 268, 269, 270, 271, 272)

The method according to any one of claims 265-272, wherein the initial concentration of each of the T cell growth factors in the cell culture medium of the TILs is each independently at least about 300 IU/mL.

### Claim 274 (depends on 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273)

The method according to any one of claims 184-273, wherein the TILs are TILs derived from tumor tissue debris and/or TILs resuscitated after cryopreservation.

### Claim 275 (depends on 274)

The method according to claim 274, wherein the debris has a volume of about 1 mm3 to about 27 mm3.

### Claim 276

A method for culturing tumor-infiltrating lymphocytes (TILs), comprising:
(A) contacting a first TIL population derived from tumor tissues and not expanded in vitro with T cell growth factors, wherein a second TIL population is obtained via the step (A);
(B) improving the expression and/or enhancing the activity of at least one cytokine of the second TIL population, and contacting the TTLs with a CD28 agonist, wherein a third TIL population is obtained via the step (B).

### Claim 277

A method for culturing tumor-infiltrating lymphocytes (TILs), comprising:
(A) resuscitating and/or continuing culturing an in vitro TIL population to obtain a second TIL population, wherein the in vitro TIL population comprises a TIL population obtained by in vitro expansion of a first TIL population derived from tumor tissues and not expanded in vitro;
(B) improving the expression and/or enhancing the activity of at least one cytokine of the second TIL population, and contacting the TTLs with a CD28 agonist, wherein a third TIL population is obtained via the step (B).

### Claim 278 (depends on 277)

The method according to claim 277, wherein the in vitro TIL population comprises a TIL population obtained by contacting the first TIL population with T cell growth factors.

### Claim 279 (depends on 277, 278)

The method according to any one of claims 277-278, wherein the in vitro TIL population comprises a TIL population obtained by cryopreserving the first TIL population.

### Claim 280 (depends on 276, 277, 278, 279)

The method according to any one of claims 276-279, wherein the step (A) is carried out for about 7 days to about 14 days.

### Claim 281 (depends on 276, 277, 278, 279, 280)

The method according to any one of claims 276-280, wherein the step (B) is carried out for about 7 days to about 14 days.

### Claim 282 (depends on 276, 277, 278, 279, 280, 281)

The method according to any one of claims 276-281, wherein TILs obtained by improving the expression and/or enhancing the activity of at least one cytokine of the TILs show improved TIL properties, compared to TILs with unchanged expression and/or activity of the cytokine.

### Claim 283 (depends on 282)

The method according to claim 282, wherein the improved TIL properties comprise one or more properties selected from the group consisting of: increased number of TIL cells, increased proportion of viable cells, enhanced persistence, improved proportion of T cell subpopulations, enhanced cytokine secretion capacity, enhanced tumor cell killing ability, enhanced T cell receptor (TCR) clonal diversity, and increased number of TIL cells in tissues.

### Claim 284 (depends on 283)

The method according to claim 283, wherein the improved proportion of T cell subpopulations comprises one or more subpopulations selected from the group consisting of: increased proportion of central memory T cells, decreased proportion of regulatory T cells, increased proportion of activated T cells, increased proportion of tumor-specific T cells, and increased proportion of stem cell-like T cells.

### Claim 285 (depends on 276, 277, 278, 279, 280, 281, 282, 283, 284)

The method according to any one of claims 276-284, wherein the TILs that have been contacted with the CD28 agonist during at least one stage of in vitro expansion show an improved gene editing effect, compared to corresponding TILs that have not been contacted with the CD28 agonist during the stage of in vitro expansion.

### Claim 286 (depends on 285)

The method according to claim 285, wherein the improved gene editing effect comprises enhanced gene knockout efficiency.

### Claim 287 (depends on 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286)

The method according to any one of claims 276-286, wherein the step of improving the expression and/or enhancing the activity of at least one cytokine of the TILs comprises introducing a nucleic acid encoding the cytokine into the TILs.

### Claim 288 (depends on 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287)

The method according to any one of claims 276-287, wherein the step of improving the expression and/or enhancing the activity of at least one cytokine of the TILs comprises introducing a vector comprising the nucleic acid into the TILs.

### Claim 289 (depends on 287, 288)

The method according to any one of claims 287-288, wherein integrating a nucleic acid encoding the cytokine into the genome of the TILs.

### Claim 290 (depends on 288, 289)

The method according to any one of claims 288-289, wherein the vector comprises a viral vector.

### Claim 291 (depends on 290)

The method according to claim 290, wherein the viral vector comprises a retroviral vector.

### Claim 292 (depends on 291)

The method according to claim 291, wherein the retroviral vector comprises a lentiviral vector.

### Claim 293 (depends on 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292)

The method according to any one of claims 276-292, wherein the cytokine comprises interleukin (IL).

### Claim 294 (depends on 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293)

The method according to any one of claims 276-293, wherein the cytokine comprises interleukin-15 (IL-15) and/or a functionally active fragment thereof.

### Claim 295 (depends on 294)

The method according to claim 294, wherein the IL-15 comprises membrane-anchored IL-15 and/or secreted IL-15.

### Claim 296 (depends on 294, 295)

The method according to any one of claims 294-295, wherein the IL-15 comprises an IL-15 domain.

### Claim 297 (depends on 296)

The method according to claim 296, wherein the IL-15 domain comprises an amino acid sequence as shown in SEQ ID NO: 3.

### Claim 298 (depends on 294, 295, 296, 297)

The method according to any one of claims 294-297, wherein the IL-15 comprises an IL-15Ra extracellular domain.

### Claim 299 (depends on 298)

The method according to claim 298, wherein the IL-15Ra extracellular domain comprises an amino acid sequence as shown in SEQ ID NO: 16.

### Claim 300 (depends on 298, 299)

The method according to any one of claims 298-299, wherein the IL-15 domain is directly or indirectly linked to the IL-15Ra extracellular domain.

### Claim 301 (depends on 300)

The method according to claim 300, wherein the indirect linkage comprises linking through a linker.

### Claim 302 (depends on 301)

The method according to claim 301, wherein the linker comprises an amino acid sequence selected from the group consisting of: SEQ ID NOs: 4-10, (SEQ ID NO: 11)l, (SEQ ID NO: 12)m, (SEQ ID NO: 13)n, (SEQ ID NO: 14)p, and (SEQ ID NO: 15)q, and any combination of the above, wherein 1, m, n, p, and q are each independently at least 1.

### Claim 303 (depends on 294, 295, 296, 297, 298, 299, 300, 301, 302)

The method according to any one of claims 294-302, wherein the IL-15 comprises a transmembrane domain.

### Claim 304 (depends on 303)

The method according to claim 303, wherein the transmembrane domain comprises an amino acid sequence as shown in any one of SEQ ID NOs: 17-22.

### Claim 305 (depends on 303, 304)

The method according to any one of claims 303-304, wherein the transmembrane domain is directly or indirectly linked to the IL-15Ra extracellular domain.

### Claim 306 (depends on 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305)

The method according to any one of claims 294-305, wherein the IL-15 comprises an intracellular domain.

### Claim 307 (depends on 306)

The method according to claim 306, wherein the intracellular domain comprises an amino acid sequence as shown in any one of SEQ ID NOs: 23-26.

### Claim 308 (depends on 306, 307)

The method according to any one of claims 306-307, wherein the intracellular domain is directly or indirectly linked to the transmembrane domain.

### Claim 309 (depends on 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308)

The method according to any one of claims 294-308, wherein the IL-15 comprises a signal peptide domain.

### Claim 310 (depends on 309)

The method according to claim 309, wherein the signal peptide domain comprises an amino acid sequence as shown in SEQ ID NO: 2.

### Claim 311 (depends on 309, 310)

The method according to any one of claims 309-310, wherein the signal peptide domain is directly or indirectly linked to the IL-15 domain.

### Claim 312 (depends on 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311)

The method according to any one of claims 294-311, wherein the functionally active fragment of the IL-15 comprises an amino acid sequence as shown in SEQ ID NO: 3.

### Claim 313 (depends on 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312)

The method according to any one of claims 294-312, wherein the IL-15 comprises an amino acid sequence as shown in SEQ ID NO: 1.

### Claim 314 (depends on 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313)

The method according to any one of claims 276-313, wherein the enhanced expression of the cytokine comprises enhanced synthesis and/or secretion of the cytokine.

### Claim 315 (depends on 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314)

The method according to any one of claims 276-314, wherein the proportion of cells expressing the cytokine in the TILs obtained by improving the expression and/or enhancing the activity of at least one cytokine of the TILs is increased, compared to TTLs with unchanged expression and/or activity of the cytokine.

### Claim 316 (depends on 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315)

The method according to any one of claims 276-315, wherein the proportion of cells expressing the cytokine in the TILs obtained by improving the expression and/or enhancing the activity of at least one cytokine of the TILs is increased by at least about 5% or above, compared to TILs with unchanged expression and/or activity of the cytokine.

### Claim 317 (depends on 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316)

The method according to any one of claims 276-316, wherein in the TLs obtained by improving the expression and/or enhancing the activity of at least one cytokine of the TILs, the proportion of cells expressing the cytokine is at least about 5% or above.

### Claim 318 (depends on 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317)

The method according to any one of claims 276-317, wherein the CD28 agonist comprises an anti-CD28 antibody and/or an antigen-binding fragment thereof, CD80 and/or a functionally active fragment thereof, and/or CD86 and/or a functionally active fragment thereof.

### Claim 319 (depends on 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318)

The method according to any one of claims 276-318, comprising contacting the TILs with the CD28 agonist and the other T cell activators substantially simultaneously.

### Claim 320 (depends on 319)

The method according to claim 319, wherein the other T cell activators comprise agonists of one or more targets selected from the group consisting of: CD3, HVEM, CD40L, OX40, and 4-1BB.

### Claim 321 (depends on 319, 320)

The method according to any one of claims 319-320, wherein the other T cell activators comprise a CD3 agonist.

### Claim 322 (depends on 319, 320, 321)

The method according to any one of claims 319-321, wherein the other T cell activators comprise an anti-CD3 antibody and/or an antigen-binding fragment thereof.

### Claim 323 (depends on 319, 320, 321, 322)

The method according to any one of claims 319-322, wherein the step of contacting the TILs with the CD28 agonist and the other T cell activators comprises one or more ways selected from the group consisting of: (1) adding the CD28 agonist and the other T cell activators into the cell culture medium of the TILs; (2) adding engineered cells expressing the CD28 agonist and the other T cell activators into the cell culture medium of the TILs; (3) adding a solid medium comprising the CD28 agonist and the other T cell activators into the cell culture medium of the TTLs.

### Claim 324 (depends on 323)

The method according to claim 323, wherein the initial concentration of the other T cell activators in the cell culture medium of the TILs is at least about 30 ng/mL.

### Claim 325 (depends on 323, 324)

The method according to any one of claims 323-324, wherein the initial concentration of the other T cell activators in the cell culture medium of the TILs is about 30 ng/mL to about 300 ng/mL.

### Claim 326 (depends on 323, 324, 325)

The method according to any one of claims 323-325, wherein the diameter of the solid medium is about 500 nm to about 10 m.

### Claim 327 (depends on 323, 324, 325, 326)

The method according to any one of claims 323-326, wherein the diameter of the solid medium is about 1 nm to about 500 nm.

### Claim 328 (depends on 326, 327)

The method according to any one of claims 326-327, wherein the diameter of the solid medium is measured by transmission electron microscopy.

### Claim 329 (depends on 323, 324, 325, 326, 327, 328)

The method according to any one of claims 323-328, wherein the solid medium comprises a polymer.

### Claim 330 (depends on 323, 324, 325, 326, 327, 328, 329)

The method according to any one of claims 323-329, wherein each mg of the solid medium comprises at least about 25 μg of the CD28 agonist and the other T cell activators.

### Claim 331 (depends on 323, 324, 325, 326, 327, 328, 329, 330)

The method according to any one of claims 323-330, comprising adding the solid medium comprising the CD28 agonist and the other T cell activators into the cell culture medium of the TILs at a proportion of the solid medium to the TTLs from about 2:1 to about 1:2.

### Claim 332 (depends on 323, 324, 325, 326, 327, 328, 329, 330, 331)

The method according to any one of claims 323-331, comprising adding the solid medium comprising the CD28 agonist and the other T cell activators into the cell culture medium of the TILs at a proportion of the solid medium to the TILs from about 1:100 to about 1:2000.

### Claim 333 (depends on 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332)

The method according to any one of claims 276-332, comprising co-culturing the TILs with the feeder cells after contacting the TILs with the CD28 agonist for at least about 2 hours.

### Claim 334 (depends on 333)

The method according to claim 333, comprising co-culturing the TILs with the feeder cells after contacting the TILs with the CD28 agonist for about 6 hours to about 72 hours.

### Claim 335 (depends on 333, 334)

The method according to any one of claims 333-334, comprising co-culturing the TILs with the feeder cells after contacting the TILs with the CD28 agonist for about 12 hours to about 48 hours.

### Claim 336 (depends on 333, 334)

The method according to any one of claims 333-334, comprising co-culturing the TILs with the feeder cells after contacting the TTLs with the CD28 agonist for about 6 hours, about 12 hours, about 24 hours, about 48 hours, or about 72 hours.

### Claim 337 (depends on 333, 334, 335, 336)

The method according to any one of claims 333-336, wherein the feeder cells comprise antigen-presenting cells.

### Claim 338 (depends on 333, 334, 335, 336, 337)

The method according to any one of claims 333-337, wherein the feeder cells comprise one or more cells selected from the group consisting of: peripheral mononuclear cells, dendritic cells, and artificial antigen-presenting cells.

### Claim 339 (depends on 333, 334, 335, 336, 337, 338)

The method according to any one of claims 333-338, wherein the feeder cells are peripheral mononuclear cells.

### Claim 340 (depends on 333, 334, 335, 336, 337, 338, 339)

The method according to any one of claims 333-339, wherein the feeder cells are irradiated feeder cells.

### Claim 341 (depends on 333, 334, 335, 336, 337, 338, 339, 340)

The method according to any one of claims 333-340, wherein the step of co-culturing the TILs with the feeder cells comprises contacting the surface of the feeder cells with the surface of the TILs.

### Claim 342 (depends on 333, 334, 335, 336, 337, 338, 339, 340, 341)

The method according to any one of claims 333-341, wherein the step of co-culturing the TILs with the feeder cells comprises adding the feeder cells into the cell culture medium of the TILs.

### Claim 343 (depends on 333, 334, 335, 336, 337, 338, 339, 340, 341, 342)

The method according to any one of claims 333-342, wherein the method comprises adding the feeder cells into the cell culture medium of the TILs at a proportion of the feeder cells to the TILs from about 40:1 to about 400:1.

### Claim 344 (depends on 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343)

The method according to any one of claims 276-343, comprising contacting the TILs with the CD28 agonist and the T cell growth factors substantially simultaneously.

### Claim 345 (depends on 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344)

The method according to any one of claims 276-344, wherein the T cell growth factors are one or more factors selected from the group consisting of: IL-2, IL-7, IL-12, IL-15, IL-21, interferon γ, and functionally active fragments thereof.

### Claim 346 (depends on 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345)

The method according to any one of claims 276-345, wherein the T cell growth factors comprise IL-2 and/or a functionally active fragment thereof.

### Claim 347 (depends on 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346)

The method according to any one of claims 276-346, wherein the step of contacting the TILs with the T cell growth factors comprises adding the T cell growth factors into the cell culture medium of the TILs.

### Claim 348 (depends on 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347)

The method according to any one of claims 276-347, wherein the initial concentration of each of the T cell growth factors in the cell culture medium of the TILs is each independently at least about 300 IU/mL.

### Claim 349 (depends on 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348)

The method according to any one of claims 276-348, wherein the TILs are TILs derived from tumor tissue debris and/or TILs resuscitated after cryopreservation.

### Claim 350 (depends on 349)

The method according to claim 349, wherein the debris has a volume of about 1 mm3 to about 27 mm3.

### Claim 351 (depends on 1, 350)

A tumor-infiltrating lymphocyte (TIL) obtainable by the method according to any one of claims 1-350.

### Claim 352 (depends on 351)

A composition comprising the TIL as defined in claim 351.

### Claim 353 (depends on 351, 352)

A pharmaceutical composition, comprising the TIL as defined in claim 351 and/or the composition as defined in claim 352, and optionally a pharmaceutically acceptable carrier.

### Claim 354 (depends on 351, 352, 353)

A method for affecting the tumor cell growth, comprising administering to a subject the TIL as defined in claim 351, the composition as defined in claim 352 and/or the pharmaceutical composition as defined in claim 353.

### Claim 355 (depends on 351, 352, 353)

A use of the TIL as defined in claim 351, the composition as defined in claim 352 and/or the pharmaceutical composition as defined in claim 353 for the manufacture of drugs for preventing and/or treating a tumor.

### Claim 356 (depends on 355)

The use according to claim 355, wherein the tumor is a solid tumor.

### Claim 357 (depends on 355, 356)

The use according to any one of claims 355-356, wherein the tumor is one or more tumors selected from the group consisting of: melanoma, ovarian cancer, cervical cancer, lung cancer, bladder cancer, breast cancer, head and neck cancer, pancreatic cancer, liver cancer, gastric cancer, colorectal cancer, and kidney cancer.
